A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
EvolveImmune United, Inc
OncoC4, Inc.
Sotio Biotech Inc.
National Cancer Institute (NCI)
Novartis
Incyte Corporation
Jonsson Comprehensive Cancer Center
Cardiff University
Sumitomo Pharma America, Inc.
Shattuck Labs, Inc.
Memorial Sloan Kettering Cancer Center
The Affiliated Hospital of Qingdao University
Gene Surgery LLC
Shanghai Bovax Biotechnology Co., Ltd.
Corregene Biotechnology Co., Ltd
HRYZ Biotech Co.
HRYZ Biotech Co.
Xencor, Inc.
Beijing Health Guard Biotechnology, Inc
Rubius Therapeutics
Xencor, Inc.
Genocea Biosciences, Inc.
Corregene Biotechnology Co., Ltd
National Institutes of Health Clinical Center (CC)
National Institute of Allergy and Infectious Diseases (NIAID)
AIDS Malignancy Consortium
Abramson Cancer Center at Penn Medicine
Lund University Hospital
Antiva Biosciences
Antiva Biosciences
Montefiore Medical Center
Oryx GmbH & Co. KG
Mayo Clinic
Alliance for Clinical Trials in Oncology
Eli Lilly and Company
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
AIDS Malignancy Consortium
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
NYU Langone Health
Mannkind Corporation
Case Comprehensive Cancer Center